

YOU ARE CORDIALLY INVITED TO A VIRTUAL PROGRAM PRESENTED BY...

A program on an FDA approved treatment option in locally advanced or mUC for patients who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.

PRESENTER

Nataliya Mar, MD
Assistant Professor
University of California Irvine
Orange, CA

DATE AND TIME

June 16, 2020
6:00 PM PT

LOCATION

Virtual

RSVP

To: <https://vision2voiceevents.com/summer/program2>
Phone:
Email:

Kindly Reply by

June 9, 2020

In the RSVP, please include your Name, Contact Information, Organization, and Specialty.

INDICATION

PADCEV (enfortumab vedotin-ejfv) is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Hyperglycemia occurred in patients treated with PADCEV, including death and diabetic ketoacidosis (DKA), in those with and without pre-existing diabetes mellitus. The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. In one clinical trial, 8% of patients developed Grade 3-4 hyperglycemia. Patients with baseline hemoglobin A1C $\geq 8\%$ were excluded. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.

Peripheral neuropathy (PN), predominantly sensory, occurred in 49% of the 310 patients treated with PADCEV in clinical trials; 2% experienced Grade 3 reactions. In one clinical trial, peripheral neuropathy occurred in patients treated with PADCEV with or without preexisting peripheral neuropathy. The median time to onset of Grade ≥ 2 was 3.8 months (range: 0.6 to 9.2). Neuropathy led to treatment discontinuation in 6% of patients. At the time of their last evaluation, 19% had complete resolution, and 26% had partial improvement. Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction of PADCEV when peripheral neuropathy occurs. Permanently discontinue PADCEV in patients that develop Grade ≥ 3 peripheral neuropathy.

Ocular disorders occurred in 46% of the 310 patients treated with PADCEV. The majority of these events involved the cornea and included keratitis, blurred vision, limbal stem cell deficiency and other events associated with dry eyes. Dry eye symptoms occurred in 36% of patients, and blurred vision occurred in 14% of patients, during treatment with PADCEV. The median time to onset to symptomatic ocular disorder was 1.9 months (range: 0.3 to 6.2). Monitor patients for ocular disorders. Consider artificial tears for prophylaxis of dry eyes and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Consider treatment with ophthalmic topical steroids, if indicated after an ophthalmic exam. Consider dose interruption or dose reduction of PADCEV for symptomatic ocular disorders.

Please see Important Safety Information continued on next page.

Click [here](#) for full Prescribing Information.



IMPORTANT SAFETY INFORMATION (CONT.)

Skin reactions occurred in 54% of the 310 patients treated with PADCEV in clinical trials. Twenty-six percent (26%) of patients had maculopapular rash and 30% had pruritus. Grade 3–4 skin reactions occurred in 10% of patients and included symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, and palmar-plantar erythrodysesthesia. In one clinical trial, the median time to onset of severe skin reactions was 0.8 months (range: 0.2 to 5.3). Of the patients who experienced rash, 65% had complete resolution and 22% had partial improvement. Monitor patients for skin reactions. Consider appropriate treatment, such as topical corticosteroids and antihistamines for skin reactions, as clinically indicated. For severe (Grade 3) skin reactions, withhold PADCEV until improvement or resolution and administer appropriate medical treatment. Permanently discontinue PADCEV in patients that develop Grade 4 or recurrent Grade 3 skin reactions.

Infusion site extravasation Skin and soft tissue reactions secondary to extravasation have been observed after administration of PADCEV. Of the 310 patients, 1.3% of patients experienced skin and soft tissue reactions. Reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2–7 days after extravasation and resolved within 1–4 weeks of peak. One percent (1%) of patients developed extravasation reactions with secondary cellulitis, bullae, or exfoliation. Ensure adequate venous access prior to starting PADCEV and monitor for possible extravasation during administration. If extravasation occurs, stop the infusion and monitor for adverse reactions.

Embryo-fetal toxicity PADCEV can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during PADCEV treatment and for 2 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PADCEV and for 4 months after the last dose.

Adverse Reactions

Serious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions ($\geq 3\%$) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, and sepsis (each 0.8%).

Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%). Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).

The most common adverse reactions ($\geq 20\%$) were fatigue (56%), peripheral neuropathy (56%), decreased appetite (52%), rash (52%), alopecia (50%), nausea (45%), dysgeusia (42%), diarrhea (42%), dry eye (40%), pruritus (26%) and dry skin (26%). The most common Grade ≥ 3 adverse reactions ($\geq 5\%$) were rash (13%), diarrhea (6%) and fatigue (6%).

Lab Abnormalities

In one clinical trial, Grade 3–4 laboratory abnormalities reported in $\geq 5\%$ were: lymphocytes decreased, hemoglobin decreased, phosphate decreased, lipase increased, sodium decreased, glucose increased, urate increased, neutrophils decreased.

Drug Interactions

Effects of other drugs on PADCEV Concomitant use with a strong CYP3A4 inhibitor may increase free MMAE exposure, which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with strong CYP3A4 inhibitors.

Specific Populations

Lactation Advise lactating women not to breastfeed during treatment with PADCEV and for at least 3 weeks after the last dose.

Hepatic impairment Avoid the use of PADCEV in patients with moderate or severe hepatic impairment.

Click [here](#) for full Prescribing Information.

For healthcare providers in Colorado, please [see](#) our required disclosure.

Astellas & Seattle Genetics Transparency Notice

Astellas Pharma US, Inc. (“Astellas”) and Seattle Genetics are subject to U.S. Federal and State transparency laws that require Astellas and Seattle Genetics to track and report meals and other transfers of value provided to certain U.S. health care professionals (including physicians). To comply with these obligations, for attendees who receive any portion of the meal provided at this program, either Astellas or Seattle Genetics will report the attendee's name and the value of the meal received. Astellas and Seattle Genetics offers you the option to attend the event but not receive the meal. Please ask the Program Organizer for more information about this opt-out option.

Additional restrictions apply to the following individuals:

For U.S. Healthcare Providers in Vermont or those affiliated with the U.S. Department of Veterans Affairs or Department of Defense: Several states and federal agencies in the United States restrict your interactions with Astellas and Seattle Genetics, including the provision of in-kind benefits (such as meals) at company-sponsored events. If you are a healthcare professional in Vermont or are affiliated with the U.S. Department of Veterans Affairs, Department of Defense, or other federal executive branch entity, [Astellas and Seattle Genetics policy prohibits providing you a meal at this program](#). If you would like to attend, but not partake in the meal, please refer to the opt-out option below.

For U.S. Licensed Prescribers in Minnesota: Under Minnesota law, Astellas and Seattle Genetics may provide meals and other transfers of value to Minnesota licensed prescribers if the [annual \(calendar year\) aggregate total](#) of all value transfers of any kind from Astellas or Seattle Genetics to a Minnesota prescriber does not exceed [\\$50,00 USD per company](#), subject to some exceptions. Astellas and Seattle Genetics have policies and procedures that are intended to help ensure compliance with this annual aggregate limit. If you have questions about your annual aggregate value transfers from Astellas or Seattle Genetics, or the impact of accepting the meal provided at this event on your annual total, please consult the Program Organizer. In addition, if you would like to attend, but not partake in the meal, please refer to the opt-out option below.

For State Government Employees: State ethics laws may prohibit you from accepting a meal. [Astellas and Seattle Genetics policy prohibits:](#) (1) **Colorado State Employees** from accepting from Astellas or Seattle Genetics more than \$50 annually in transfers of value, from each company, including meals; (2) **Louisiana State Employees** from accepting a meal that exceeds \$60 in value from each company; and (3) **New York State Employees** from accepting a meal that exceeds \$15 in value. If you would like to attend, but not partake in the meal, please refer to the opt-out option below.

For Foreign Healthcare Providers: Some foreign countries restrict the provision of or require the reporting of in-kind benefits (such as meals) to healthcare professionals at company-sponsored events. Astellas and Seattle Genetics has policies and procedures that are intended to help ensure compliance with these requirements and restrictions. To help ensure compliance with applicable requirements, Astellas and Seattle Genetics policy prohibits providing a meal to you in conjunction with this event. If you would like to attend, but not partake in the meal, please refer to the opt-out option below.

Opt-Out Option: Astellas and Seattle Genetics offers an opt-out option that allows you to still attend this event but not receive the meal. Please ask the Program Organizer for more information about the opt-out option.

Astellas has adopted and Seattle Genetics complies with the PhRMA Code on Interactions with Healthcare Professionals, which is designed to foster ethical relationships with healthcare professionals. In accordance with the PhRMA Code, we will not pay for the expenses of a healthcare professional's spouse or guest, and such individuals should not attend the program, unless they have a bona fide professional interest in the information being shared at the program. We appreciate your understanding and support of our commitment to these ethical standards. 81-0439-PM